Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis.
OBJECTIVE
To investigate the efficacy of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with acute bacterial meningitis (ABM).


METHODS
Prospective double blind, placebo controlled randomized study.


METHODS
Pediatric services of a tertiary care teaching and referral hospital.


METHODS
Children 2 months to 12 years with a diagnosis of acute bacterial meningitis admitted between June 2002 to September 2003.


METHODS
Subjects were assigned randomly to receive dexamethasone, glycerol, dexamethasone+glycerol or placebo. Neurological and hearing impairment was assessed at discharge and after 1 month.


RESULTS
58 children (48 boys, 10 girls), mean age 50.2 +/- 41.0 months, were studied. Twelve patients received dexamethasone, 13 glycerol, 20 dexamethasone + glycerol and 13 placebo. Bacterial etiology was ascertained in 24 patients: Streptococcus pneumoniae-10, H influenzae b-7, Staph. aureus-5 and others-2. Three (5.2%) children died during hospital stay and 55 survived. Seven (12%) patients had neurological sequelae (3 in glycerol, 3 in dexamethasone+glycerol, 1 in placebo group, P = 0.29), and 10 patients (17%) had hearing sequelae (2 in glycerol, 3 in dexamethasone, 2 dexamethasone + glycerol and 3 in placebo group, P = 0.68).


CONCLUSIONS
No significant difference was seen in neurological or hearing outcome with use of either glycerol or dexamethasone in children with acute bacterial meningitis.
Sankar
Jhuma
J
Department of Pediatrics, Advanced Pediatric Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Singhi
P
P
Bansal
A
A
Ray
P
P
Singhi
S
S
D000208:Acute Disease; D000284:Administration, Oral; D002648:Child; D002675:Child, Preschool; D003907:Dexamethasone / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005990:Glycerol / Q000627:therapeutic use*; D034381:Hearing Loss / Q000209:etiology / Q000517:prevention & control*; D006320:Hearing Tests; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D016920:Meningitis, Bacterial / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000209:etiology / Q000517:prevention & control*; D009483:Neuropsychological Tests; D011336:Probability; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D003907:Dexamethasone; D005990:Glycerol